TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39217809

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a (125 µg subcutaneous every two weeks)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Interferon beta-1a (30 µg intramuscular once a week)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Number of subjects: 168

Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 168
Study: 39217835

Group type: EXPERIMENTAL
Intervention: Looking at a dog (VISUAL)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Petting a dog (TACTILE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Performing tricks with a dog (ACTIVE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No dog present (CONTROL)
Number of subjects: 33
Study: 39218041

Group type: EXPERIMENTAL
Intervention: Single-fraction preoperative partial breast irradiation (PBI) 20 Gy
Number of subjects: 13
Study: 39218164

Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA test
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: FIT OC-SENSOR
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: FIT FOB-Gold
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Stool-based post-polypectomy surveillance strategies
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA-based surveillance
Number of subjects: 3453

Group type: EXPERIMENTAL
Intervention: FIT-based surveillance
Number of subjects: 3453
Study: 39218222

Group type: EXPERIMENTAL
Intervention: Hepatic OXPHOS capacity
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: FPG ≤100 mg/dl
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: FPG >100 mg/dl
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Liver lipid content threshold value of 24%
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Presence of prediabetes
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Presence of MASLD
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Increasing liver lipid contents and plasma glucose concentrations
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Metabolically active drugs
Number of subjects: 65
Study: 39218235

Group type: EXPERIMENTAL
Intervention: Calcifediol treatment
Number of subjects: 707

Group type: COMPARATOR
Intervention: Glucocorticoids treatment
Number of subjects: 707

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 707
Study: 39218309

Group type: EXPERIMENTAL
Intervention: SCB-2019
Number of subjects: 6695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6695
Study: 39218777

Group type: COMPARATOR
Intervention: Immediate soft-tissue augmentation (STA) during the same surgical procedure (Control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Delayed soft-tissue augmentation (STA) performed 3 months later (Test group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 39218855

Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Number of subjects: 0
Study: 39218875

Group type: EXPERIMENTAL
Intervention: Gender-affirming hormonal therapy (GAHT) for 12 weeks
Number of subjects: 36
Study: 39218883

Group type: EXPERIMENTAL
Intervention: Urban school-based WASH programme (Project WISE)
Number of subjects: 6229

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 6229
Study: 39218935

Group type: EXPERIMENTAL
Intervention: Reduced-dose chemotherapy (RDC) followed by blinatumomab for 2 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Blinatumomab extended to 4 weeks for those failing to achieve CRc
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (RDC + blinatumomab)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival rates
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 35
Study: 39218948

Group type: EXPERIMENTAL
Intervention: mFCCA short version
Number of subjects: 318
Study: 39218965

Group type: EXPERIMENTAL
Intervention: Highest SBP group
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: Lowest SBP group
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: SBP categories
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: DBP categories
Number of subjects: 2845

Group type: EXPERIMENTAL
Intervention: Optimal BP levels
Number of subjects: 2845
Study: 39219163

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 224

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 224
Study: 39219192

Group type: EXPERIMENTAL
Intervention: Treatment for HCV
Number of subjects: 0
Study: 39219209

Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMHs)
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Superficial cerebral microbleeds (CMBs)
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Deep cerebral microbleeds (CMBs)
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Lacunar infarction
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Combined diagnostic model including CVD biomarkers
Number of subjects: 1352
Study: 39219320

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP; CIMZIA™)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population PK model based on data from the CHERISH study (NCT04163016)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior information based on a population PK model for certolizumab pegol in non-pregnant adult patients (NCT04740814)
Number of subjects: 0
Study: 39219437

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (pooled)
Number of subjects: 7629

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7629
Study: 39219492

Group type: EXPERIMENTAL
Intervention: Omaveloxolone 150 mg orally once daily on an empty stomach
Number of subjects: 0
Study: 39219857

Group type: EXPERIMENTAL
Intervention: Intradermal Bacillus Calmette-Guérin (BCG) injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39219956

Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium hypochlorite (3%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diode laser (940 nm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (2,780 nm)
Number of subjects: 60
Study: 39220267

Group type: EXPERIMENTAL
Intervention: Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scale (VABS-III)
Number of subjects: 67
Study: 39220298

Group type: EXPERIMENTAL
Intervention: TMB ≥4 mutations/Mb
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Positive PD-L1 TPS (≥1%)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: TMB ≥10 mutations/Mb
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: PD-L1 TPS positive (≥1%)
Number of subjects: 388
Study: 39220343

Group type: EXPERIMENTAL
Intervention: Ohnut used during sexual encounters (average 72.4% of encounters)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waitlist control (no Ohnut used)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ohnut acceptability questionnaire
Number of subjects: 31
Study: 39220573

Group type: EXPERIMENTAL
Intervention: CM310 300 mg subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and 300 mg CM310 Q2W for a total of 14 doses during the maintenance period.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and placebo Q2W for a total of 14 doses during the maintenance period.
Number of subjects: 180
Study: 39220578

Group type: EXPERIMENTAL
Intervention: Quantitative Transmission (QT) Scan
Number of subjects: 430

Group type: COMPARATOR
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 430
Study: 39220658

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 39220734

Group type: EXPERIMENTAL
Intervention: Active tVNS with HABIT-ILE training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham tVNS with HABIT-ILE training
Number of subjects: 44
Study: 39221160

Group type: EXPERIMENTAL
Intervention: UNISALUD intervention (11 sessions with interactive elements such as videos, audio, and infographics)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (waiting list, treatment after 27 days)
Number of subjects: 176
Study: 39221228

Group type: EXPERIMENTAL
Intervention: DESIRE intervention (training programme for health professionals, patient decision aid, kidney service consultation)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study: 39221451

Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39221503

Group type: EXPERIMENTAL
Intervention: BPTB graft
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft
Number of subjects: 114

Group type: COMPARATOR
Intervention: BPTB graft and Hamstring tendon graft
Number of subjects: 114
Study: 39221516

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 39221566

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 0
Study: 39221567

Group type: EXPERIMENTAL
Intervention: Long-COVID
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 51

Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 51
Study: 39221611

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 39221629

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation with cryoablation (n=64)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham procedure with phrenic nerve pacing (n=62)
Number of subjects: 126
Study: 39221651

Group type: EXPERIMENTAL
Intervention: CSL112 (6 g, four weekly infusions)
Number of subjects: 18219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18219
Study: 39221769

Group type: EXPERIMENTAL
Intervention: Multivoxel neuroreinforcement (1, 3, or 5 sessions)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control phobia (not specified)
Number of subjects: 23
Study: 39221824

Group type: EXPERIMENTAL
Intervention: Mavacamten (n=56) for 56 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (n=52) transitioned to Mavacamten from weeks 16 to 56 (40-week exposure)
Number of subjects: 112
Study: 39222035

Group type: EXPERIMENTAL
Intervention: Flecainide for 3 months (150 mg once daily in a sustained-release dose)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Flecainide for 6 months (150 mg once daily in a sustained-release dose)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard of care (no additional treatment for 6 months)
Number of subjects: 186
Study: 39222182

Group type: EXPERIMENTAL
Intervention: F/TAF-based PrEP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Integrated PrEP/STI services
Number of subjects: 30
Study: 39222277

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 256

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 256
Study: 39222281

Group type: EXPERIMENTAL
Intervention: Accelerometry in patients with HF
Number of subjects: 151

Group type: COMPARATOR
Intervention: Accelerometry in healthy controls
Number of subjects: 151

Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA) in healthy controls
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) in patients with HF
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of average acceleration with 6-minute walking test (6MWT) in patients with HF
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of average acceleration with maximal oxygen uptake in patients with HF
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of accelerometer measurements with LVEF in patients with HF
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Correlation of accelerometer measurements with NT-proBNP in patients with HF
Number of subjects: 151
Study: 39222348

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prescription Digital Therapeutics (PDT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ideal Use (Fidelity)
Number of subjects: 18
Study: 39222391

Group type: EXPERIMENTAL
Intervention: Oral preparation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rectal enema
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (oral preparation and rectal enema)
Number of subjects: 40
Study: 39222408

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39222436

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 907
Study: 39222437

Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD)
Number of subjects: 20
Study: 39222513

Group type: EXPERIMENTAL
Intervention: Hemoccult ICT
Number of subjects: 3761

Group type: EXPERIMENTAL
Intervention: Hemosure iFOB
Number of subjects: 3761

Group type: EXPERIMENTAL
Intervention: OC-Light S FIT
Number of subjects: 3761

Group type: EXPERIMENTAL
Intervention: QuickVue iFOB
Number of subjects: 3761

Group type: EXPERIMENTAL
Intervention: OC-Auto FIT (threshold >100 ng/mL)
Number of subjects: 3761

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 3761
Study: 39222579

Group type: EXPERIMENTAL
Intervention: CatBoost classifier
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Random Forest classifier
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Support Vector Machine classifier
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Baseline acoustic and MFCC features
Number of subjects: 48
Study: 39222642

Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg in SELECT, STEP-HFpEF, and STEP-HFpEF DM; 1.0 mg in FLOW)
Number of subjects: 3743
Study: 39222649

Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg twice daily
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 39222687

Group type: EXPERIMENTAL
Intervention: 4 oz beef patty
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4 oz SBMA
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 oz SBMA
Number of subjects: 0
Study: 39222701

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel
Number of subjects: 2559

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2559

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 2559
Study: 39222737

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39222896

Group type: EXPERIMENTAL
Intervention: TEER group (TriClip System + medical therapy)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Control group (medical therapy alone)
Number of subjects: 572
Study: 39222964

Group type: EXPERIMENTAL
Intervention: DOT Diary (automated directly observed therapy app)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-of-care (control)
Number of subjects: 100
Study: 39223284

Group type: EXPERIMENTAL
Intervention: AI-guided screening using a digital stethoscope
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: 12-lead AI-electrocardiogram model
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1232
Study: 39223302

Group type: EXPERIMENTAL
Intervention: Insufflation of carbon dioxide (CO2) during laparoscopic surgery, specific dosage and duration not mentioned
Number of subjects: 0
Study: 39223359

Group type: EXPERIMENTAL
Intervention: VBM and DTI imaging
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Motor deficit assessments (Nine peg hole test, dynamometer, Hand-Tapping Test)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Corticospinal fractional anisotropy (FA)
Number of subjects: 21
Study: 39223424

Group type: EXPERIMENTAL
Intervention: REMOTE (live video urogenital rehabilitation intervention protocol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: SELF (home-based pre-recorded video protocol)
Number of subjects: 28
Study: 39223470

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 204

Group type: COMPARATOR
Intervention: Intravenous analgesia
Number of subjects: 204
Study: 39223504

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous Zoledronic acid (ZOL)
Number of subjects: 108
Study: 39223526

Group type: EXPERIMENTAL
Intervention: Nebulized N-acetylcysteine (NAC) therapy over 12 weeks
Number of subjects: 100
Study: 39223545

Group type: EXPERIMENTAL
Intervention: Raltitrexed (3 mg/m²) plus Irinotecan
Number of subjects: 108
Study: 39223593

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 223
Study: 39223596

Group type: EXPERIMENTAL
Intervention: JoyPop™ app (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study: 39223600

Group type: EXPERIMENTAL
Intervention: mhGAP-Remote (1 in-person session + 8 weeks of SMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mhGAP-Standard (4 to 6 in-person sessions)
Number of subjects: 0
Study: 39223617

Group type: EXPERIMENTAL
Intervention: modified prolonged exposure therapy (mPE) + treatment as usual (TAU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: modified prolonged exposure therapy (mPE)
Number of subjects: 22
Study: 39223657

Group type: EXPERIMENTAL
Intervention: Limited fasciectomy with autologous adipose tissue grafting
Number of subjects: 150

Group type: COMPARATOR
Intervention: Limited fasciectomy alone
Number of subjects: 150
Study: 39223952

Group type: EXPERIMENTAL
Intervention: Indo-Mediterranean diet (IMD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calorie-restricted diet (CRD)
Number of subjects: 39
Study: 39223953

Group type: EXPERIMENTAL
Intervention: Physical therapy sessions
Number of subjects: 37
Study: 39223992

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA)
Number of subjects: 980
Study: 39224057

Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model with Neuromuscular Inhibition Technique (FDM with NIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fascial Distortion Model alone (FDM)
Number of subjects: 54
Study: 39224116

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 0
Study: 39224138

Group type: EXPERIMENTAL
Intervention: Diet containing fresh, lean beef
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diet containing plant alternatives
Number of subjects: 17
Study: 39224188

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Number of subjects: 88
Study: 39224580

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture therapy (PPT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 50
Study: 39224668

Group type: EXPERIMENTAL
Intervention: Guided digital CBT-I intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39224752

Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation (REHAB+)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Center-based cardiac rehabilitation
Number of subjects: 900
Study: 39224799

Group type: EXPERIMENTAL
Intervention: Video-assisted telenursing
Number of subjects: 0
Study: 39224811

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with paclitaxel (50 mg/m2) and carboplatin (AUC=2) followed by concurrent CRT with the same regimen, radiation dose of 40 Gy over 16 fractions (2.5 Gray/fraction).
Number of subjects: 54
Study: 39224901

Group type: EXPERIMENTAL
Intervention: CMAB015 (150 mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Secukinumab (Cosentyx)
Number of subjects: 130
Study: 39224986

Group type: EXPERIMENTAL
Intervention: Nurse-led family empowerment program (experimental group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 58
Study: 39225259

Group type: EXPERIMENTAL
Intervention: Plozasiran 25 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plozasiran 50 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plozasiran (both doses)
Number of subjects: 75
Study: 39225258

Group type: EXPERIMENTAL
Intervention: Edoxaban monotherapy
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (edoxaban plus a single antiplatelet agent)
Number of subjects: 1040
Study: 39225267

Group type: EXPERIMENTAL
Intervention: Asundexian 50 mg once daily
Number of subjects: 14810

Group type: COMPARATOR
Intervention: Apixaban (standard dose)
Number of subjects: 14810
Study: 39225278

Group type: EXPERIMENTAL
Intervention: Finerenone (20 mg or 40 mg once daily)
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study: 39225327

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 500
Study: 39225384

Group type: EXPERIMENTAL
Intervention: LifeFirst SWASTH program (pamphlet explaining tobacco's harmful effects, brief cessation advice, referral for free telephone counseling for 6 months)
Number of subjects: 1687

Group type: COMPARATOR
Intervention: Pamphlet explaining tobacco's harmful effects (no brief advice or counseling)
Number of subjects: 1687